1. CCL28 may play dual roles in mucosal immunity as a chemoattractant for cells expressing CCR10 and/or CCR3 such as plasma cells and also as a broad-spectrum antimicrobial protein secreted into low-salt body fluids. PMID: 12538707
2. CCR10 and its mucosal epithelial ligand CCL28 have roles in the migration of circulating IgA plasmablasts PMID: 12671049
3. CCL28 produced by keratinocytes is mediated by different signal pathways from CCL27, and both CCL27 and CCL28 are involved in the pathogenesis of inflammatory skin diseases. PMID: 16433680
4. CCL28 is one link between microbial insult and the exacerbation of pathologies such as asthma, through an NFkappaB-dependent mechanism PMID: 16581045
5. Expression of CCL28 by epithelial cells from chronically inflamed liver in response to microbial products or interleukin-1 provides a signal to localize CCR10-expressing regulatory T cells at mucosal surfaces. PMID: 16785557
6. CCL28 mediates mucosal immunity in HIV exposure and infection PMID: 17912348
7. These studies are the first to show increased CCL28 production during gastrointestinal infection in humans and provide an explanation for the large influx of IgA-secreting cells to the gastric mucosa in H. pylori-infected individuals. PMID: 18426876
8. There was a robust migration of specific IgA- and IgM-antibody-secreting cells induced by Salmonella vaccination toward the mucosal chemokines CCL25 and CCL28 PMID: 19003934
9. data reinforce concept that CCL28 may contribute to the pathogenesis of atopic dermatitis probably through selective migration & infiltration of effector/memory T-helper-2 cells in the skin; CCL28 may represent a prognostic marker for disease severity PMID: 19659860
10. These results indicate a role for IL-17A in the human lung by enhancing the expression of CCL28 and hence driving the recruitment of IgE-secreting B cells. PMID: 21447959
11. tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis PMID: 21753853
12. CCL28 is a potent growth-promoting factor with the ability to support the in vitro and in vivo functional properties of cultured human hematopoietic cells. PMID: 23509159
13. CCL28-CCR3 interactions are involved in the homeostatic trafficking of CD4(+) T cells to the upper airways. PMID: 24917456
14. CCL28 was absent in saliva of primary Sjogren's syndrome patients. This finding did not correlate with salivary IgA levels. PMID: 25567740
15. High CCL28 gene methylation is associated with gastric tumor aggressiveness. PMID: 25740824
16. disease severity of atopic dermatitis in children is not correlated to the level of CCL28, but rather related to that of total IgE PMID: 26642722
17. Results show that CCL28 expression was up-regulated under hypoxic condition in lung adenocarcinoma cells. Besides other effects on tumor biology such as immunosuppression, CCL28 could promote angiogenesis in lung adenocarcinoma by directly activating its receptor, CCR3, on microvascular endothelial cells. PMID: 27250766
18. HCC recruits Tregs to promote angiogenesis under hypoxic condition by upregulating CCL28 expression. These findings establish a link between Tregs and hypoxia in HCC growth and may provide a new potential therapeutic target for treating HCC. PMID: 27716621
19. our results show for the first time that CCL28 contributes to breast cancer progression through the ERK/MAPKmediated anti-apoptotic and metastatic signaling pathway. Antagonists of CCL28 and the MAPK signaling pathway may be used synergistically to treat breast cancer patients. PMID: 28713975
20. this review discusses the role of CCL28 in innate and adaptive immunity PMID: 28843907

HGNC: 17700

OMIM: 605240

KEGG: hsa:56477

STRING: 9606.ENSP00000354416

UniGene: Hs.656904